Cargando…

The case for FAT10 as a novel target in fatty liver diseases

Human leukocyte antigen F locus adjacent transcript 10 (FAT10) is a ubiquitin-like protein that targets proteins for degradation. TNFα and IFNγ upregulate FAT10, which increases susceptibility to inflammation-driven diseases like nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wimalarathne, Madushika M., Wilkerson-Vidal, Quiana C., Hunt, Emily C., Love-Rutledge, Sharifa T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665838/
https://www.ncbi.nlm.nih.gov/pubmed/36386217
http://dx.doi.org/10.3389/fphar.2022.972320
_version_ 1784831373819772928
author Wimalarathne, Madushika M.
Wilkerson-Vidal, Quiana C.
Hunt, Emily C.
Love-Rutledge, Sharifa T.
author_facet Wimalarathne, Madushika M.
Wilkerson-Vidal, Quiana C.
Hunt, Emily C.
Love-Rutledge, Sharifa T.
author_sort Wimalarathne, Madushika M.
collection PubMed
description Human leukocyte antigen F locus adjacent transcript 10 (FAT10) is a ubiquitin-like protein that targets proteins for degradation. TNFα and IFNγ upregulate FAT10, which increases susceptibility to inflammation-driven diseases like nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC). It is well established that inflammation contributes to fatty liver disease, but how inflammation contributes to upregulation and what genes are involved is still poorly understood. New evidence shows that FAT10 plays a role in mitophagy, autophagy, insulin signaling, insulin resistance, and inflammation which may be directly associated with fatty liver disease development. This review will summarize the current literature regarding FAT10 role in developing liver diseases and potential therapeutic targets for nonalcoholic/alcoholic fatty liver disease and hepatocellular carcinoma.
format Online
Article
Text
id pubmed-9665838
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96658382022-11-15 The case for FAT10 as a novel target in fatty liver diseases Wimalarathne, Madushika M. Wilkerson-Vidal, Quiana C. Hunt, Emily C. Love-Rutledge, Sharifa T. Front Pharmacol Pharmacology Human leukocyte antigen F locus adjacent transcript 10 (FAT10) is a ubiquitin-like protein that targets proteins for degradation. TNFα and IFNγ upregulate FAT10, which increases susceptibility to inflammation-driven diseases like nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC). It is well established that inflammation contributes to fatty liver disease, but how inflammation contributes to upregulation and what genes are involved is still poorly understood. New evidence shows that FAT10 plays a role in mitophagy, autophagy, insulin signaling, insulin resistance, and inflammation which may be directly associated with fatty liver disease development. This review will summarize the current literature regarding FAT10 role in developing liver diseases and potential therapeutic targets for nonalcoholic/alcoholic fatty liver disease and hepatocellular carcinoma. Frontiers Media S.A. 2022-11-01 /pmc/articles/PMC9665838/ /pubmed/36386217 http://dx.doi.org/10.3389/fphar.2022.972320 Text en Copyright © 2022 Wimalarathne, Wilkerson-Vidal, Hunt and Love-Rutledge. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wimalarathne, Madushika M.
Wilkerson-Vidal, Quiana C.
Hunt, Emily C.
Love-Rutledge, Sharifa T.
The case for FAT10 as a novel target in fatty liver diseases
title The case for FAT10 as a novel target in fatty liver diseases
title_full The case for FAT10 as a novel target in fatty liver diseases
title_fullStr The case for FAT10 as a novel target in fatty liver diseases
title_full_unstemmed The case for FAT10 as a novel target in fatty liver diseases
title_short The case for FAT10 as a novel target in fatty liver diseases
title_sort case for fat10 as a novel target in fatty liver diseases
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665838/
https://www.ncbi.nlm.nih.gov/pubmed/36386217
http://dx.doi.org/10.3389/fphar.2022.972320
work_keys_str_mv AT wimalarathnemadushikam thecaseforfat10asanoveltargetinfattyliverdiseases
AT wilkersonvidalquianac thecaseforfat10asanoveltargetinfattyliverdiseases
AT huntemilyc thecaseforfat10asanoveltargetinfattyliverdiseases
AT loverutledgesharifat thecaseforfat10asanoveltargetinfattyliverdiseases
AT wimalarathnemadushikam caseforfat10asanoveltargetinfattyliverdiseases
AT wilkersonvidalquianac caseforfat10asanoveltargetinfattyliverdiseases
AT huntemilyc caseforfat10asanoveltargetinfattyliverdiseases
AT loverutledgesharifat caseforfat10asanoveltargetinfattyliverdiseases